AIDS TREATMENT NEWS #136, October 11, 1991
Denny Smith
Oncolysin B was developed by ImmunoGen, Inc., of Cambridge, Massachusetts, which already has the drug under investigation for the treatment of certain leukemias and non-AIDS-related lymphoma. In those trials, Oncolysin B has been found not to decrease white cell counts, which is one of the serious drawbacks of more established therapies.
ImmunoGen told us that the current trials are expected to fill quickly, but that the drug is also expected to pass safety questions quickly. When that happens, larger efficacy trials will open to recruitment. Meanwhile, an additional protocol designed to combine Oncolysin B with a standard chemotherapy regimen is planned for the near future. For any of these trials, the number for interested physicians to call is 800/446-9633 or 617/661-9312, between 8 a.m. and 6 p.m. Eastern time.
911011
ATN13604
Copyright © 1991 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .